Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05813275 · ClinicalTrials.gov registry record · Phase 3

Parallel-Arm Study to Compare AD109 to Placebo With Patients With OSA (SynAIRgy Study)

A Phase 3 study, sponsored by Apnimed.

Completed
Registry status
Phase 3
Development phase
646
Enrollment target

NCT05813275: Completed Phase 3 study, sponsored by Apnimed.

NCT05813275 is a Phase 3 study that has completed, run by Apnimed. The registered enrollment target is 646 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (16% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05813275, a Phase 3 study, has completed, sponsored by Apnimed.

COMPLETED
Registry status
Phase 3
Development phase
646 participants
Enrollment target

Study Summary

This is a Phase 3 Randomized Double-Blind Placebo-Controlled 6-month Parallel-Arm Study to Compare a Fixed Dose Combination of AD109 to Placebo in Obstructive Sleep Apnea.

Primary Outcome

AHI, Apnea-Hypopnea Index, is the number of apneas or hypopneas recorded via polysomnography during the study per hour of sleep. Apnea is defined as a cessation of airflow lasting at least 10 seconds, hypopnea as a decrease in airflow by at least 30% from baseline for at least 10 seconds occurring with a drop in oxygen saturation (SpO2) by at least 4%.

Interventions

  • DRUG Placebo
  • DRUG AD109

Trial Details

FieldValue
Enrollment Target 646 participants
Start Date 2023-09-16
Est. Completion 2025-03-14
Phase Phase 3
Apnimed

12 total trials

What the finished NCT05813275 record still lists

NCT05813275 is an interventional study that assigns participants to a tested intervention. The registered 646 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (16% lower).

The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.

NCT05813275 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT05813275 about?

NCT05813275 is a clinical study titled "Parallel-Arm Study to Compare AD109 to Placebo With Patients With OSA (SynAIRgy Study)". This is a Phase 3 Randomized Double-Blind Placebo-Controlled 6-month Parallel-Arm Study to Compare a Fixed Dose Combination of AD109 to Placebo in Obstructive Sleep Apnea.

What is the current status of trial NCT05813275?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 646 participants. The study started on 2023-09-16. Estimated completion is 2025-03-14.

What interventions are being tested in trial NCT05813275?

The interventions under investigation include: Placebo (DRUG), AD109 (DRUG).

Who is sponsoring clinical trial NCT05813275?

This trial is sponsored by Apnimed, which has 12 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT05813275's enrollment target sits among peer trials

646 572nd of 2000 higher than 1,429 of 2,000 other Phase 3 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04863222 · 646 participants · Phase 4

    Clinical and Radiographic Success of MTA vs Biodentine

  • NCT07012395 · 645 participants · Phase 2

    A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis

  • NCT07027306 · 648 participants

    The Osteoporotic Fracture Classification-based Scoring System for Treatment Decision in Thoracolumbar Osteoporotic Fractures

  • NCT07164456 · 648 participants · NA

    Together Stronger: A Family-centered Lifestyle Intervention for Black Prostate Cancer Survivors and Their Caregivers

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05813275, the US trial registry maintained by the National Library of Medicine. NCT05813275 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.